默沙东特效药副作用？

Novel coronavirus pneumonia (COVID-19) is caused by the new coronavirus (SARS-CoV-2). Common symptoms include fever, sore throat, cough, difficulty breathing, and lack of energy. In the "New Coronavirus Pneumonia Treatment Guidelines" released by the National Institutes of Health, two small molecule oral drugs, nematvir tablets/ritonavir tablets and (molnupiravir), are clearly recommended for non-hospitalized COVID-19 patients. Among them, Merck's monupivir has attracted a lot of attention. So, what are the side effects of Merck's specific drug?

Merck’s Monupivir specific drug effect

The MK-4482-002 study, named after Mjollnir, is a key phase II/III clinical study to support the application for marketing authorization of monopivir. On October 1, 2021, its interim results were released. The data were optimistic and the trial was terminated early. The results of the interim analysis showed that 29 days after randomization, 7.3% of patients treated with monopivir were hospitalized and 0 died, while 14.1% of patients treated with placebo were hospitalized and 8 died. The trial results combining all enrolled patients showed that among the 1,433 patients participating in the trial, monupivir reduced the risk of hospitalization or death from 9.7% in the placebo group to 6.8% in the monupivir group, with an absolute risk reduction of 3.0% and a relative risk reduction of 30%. Nine deaths were reported in the placebo group and one death was reported in the monupivir group, resulting in an 89% lower risk of death in the monupivir group compared with placebo.

MSD Monupivir side effects

The main symptoms observed in the experiment include rash, floating dizziness, headache, urticaria, diarrhea, erythema angioedema, toxic rash, nausea, vomiting, etc.

Recommended related articles: